Literature DB >> 23749823

Central nervous system relapse in a patient with acute promyelocytic leukaemia: does the risk stratification matter?

Deniz Goren Sahin1, Eren Gunduz, Olga Meltem Akay, Zafer Gulbas.   

Abstract

Extramedullary relapse is an uncommon complication of acute promyelocytic leukaemia (APL). The most common site of extramedullary relapse is the central nervous system (CNS), and the majority of CNS relapses occur in patients with high-risk disease in which white blood cell count at presentation is greater than 10×10(3)/μL. The best management of such patients is still controversial. We describe a 47-year-old man with APL who developed two CNS relapses which were diagnosed through the presence of t(15;17)(q22;q21) on PCR of the cerebrospinal fluid (CSF), despite presenting initially with intermediate-risk disease. We conclude that the intermediate risk group is very heterogeneous and these patients sometimes may behave like high-risk patients. Also, clinicians should take into account symptoms that can be related to CNS relapse in patients with APL and consider lumbar puncture even if radiological imaging does not reveal anything.

Entities:  

Mesh:

Year:  2013        PMID: 23749823      PMCID: PMC3702910          DOI: 10.1136/bcr-2013-009456

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.

Authors:  V Mathews; P Balasubramanian; R V Shaji; B George; M Chandy; A Srivastava
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

2.  Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.

Authors:  W Y Au; S K Ma; C Ooi; R Liang; Y L Kwong
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

Review 3.  Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.

Authors:  Jae H Park; Martin S Tallman
Journal:  Oncology (Williston Park)       Date:  2011-07       Impact factor: 2.990

Review 4.  Treatment of relapsed or refractory acute promyelocytic leukemia.

Authors:  Martin S Tallman
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

Review 5.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

6.  Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

Authors:  Pau Montesinos; Joaquín Díaz-Mediavilla; Guillermo Debén; Virginia Prates; Mar Tormo; Vicente Rubio; Inmaculada Pérez; Isolda Fernández; Maricruz Viguria; Chelo Rayón; José González; Javier de la Serna; Jordi Esteve; Juan M Bergua; Concha Rivas; Marcos González; Jose D González; Silvia Negri; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

7.  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.

Authors:  Miguel A Sanz; Guillermo Martín; Marcos González; Angel León; Chelo Rayón; Concha Rivas; Dolors Colomer; Elena Amutio; Francisco J Capote; Gustavo A Milone; Javier De La Serna; José Román; Eva Barragán; Juan Bergua; Lourdes Escoda; Ricardo Parody; Silvia Negri; María J Calasanz; Pascual Bolufer
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

8.  Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.

Authors:  Toru Kiguchi; Yuta Yoshino; Bo Yuan; Seiichiro Yoshizawa; Toshihiko Kitahara; Daigo Akahane; Moritaka Gotoh; Toshikazu Kaise; Hiroo Toyoda; Kazuma Ohyashiki
Journal:  Leuk Res       Date:  2009-09-04       Impact factor: 3.156

9.  Prophylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL).

Authors:  F Ravandi
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

10.  Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.

Authors:  Sabine Knipp; Norbert Gattermann; Marc Schapira; Herbert Käferstein; Ulrich Germing
Journal:  Leuk Res       Date:  2007-04-09       Impact factor: 3.156

View more
  1 in total

1.  Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.

Authors:  Hong Wang; Fenglin Cao; Jinmei Li; Limin Li; Yong Li; Ce Shi; Wenjia Lan; Dandan Li; Hui Zhao; Ying Zhang; Zhuo Zhang; Xiuhua Liu; Ran Meng; Baofeng Yang; Jin Zhou
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.